{"title":"肝素对贝伐珠单抗治疗抗体及其靶标 VEGF-А165 模型系统中抗原-抗体相互作用的影响","authors":"M. Shevelyova, E. Nemashkalova, E. Deryusheva","doi":"10.33647/2713-0428-19-3e-77-80","DOIUrl":null,"url":null,"abstract":"In this work, we studied the effect of heparin on the binding process of VEGF-A165, the most common and important growth factor, and the monoclonal antibody bevacizumab by bio-layer interferometry. A complex of the full-length bevacizumab antibody with VEGF-A165 was modeled. The data obtained can be used in therapy with this antibody, as well as in the development of other therapeutic antibodies with maximum target specificity under various conditions.","PeriodicalId":14837,"journal":{"name":"Journal Biomed","volume":"30 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of Heparin on Antigen-Antibody Interaction in a Model System of the Bevacizumab Therapeutic Antibody And its Target VEGF-А165\",\"authors\":\"M. Shevelyova, E. Nemashkalova, E. Deryusheva\",\"doi\":\"10.33647/2713-0428-19-3e-77-80\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In this work, we studied the effect of heparin on the binding process of VEGF-A165, the most common and important growth factor, and the monoclonal antibody bevacizumab by bio-layer interferometry. A complex of the full-length bevacizumab antibody with VEGF-A165 was modeled. The data obtained can be used in therapy with this antibody, as well as in the development of other therapeutic antibodies with maximum target specificity under various conditions.\",\"PeriodicalId\":14837,\"journal\":{\"name\":\"Journal Biomed\",\"volume\":\"30 6\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal Biomed\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33647/2713-0428-19-3e-77-80\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal Biomed","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33647/2713-0428-19-3e-77-80","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Effect of Heparin on Antigen-Antibody Interaction in a Model System of the Bevacizumab Therapeutic Antibody And its Target VEGF-А165
In this work, we studied the effect of heparin on the binding process of VEGF-A165, the most common and important growth factor, and the monoclonal antibody bevacizumab by bio-layer interferometry. A complex of the full-length bevacizumab antibody with VEGF-A165 was modeled. The data obtained can be used in therapy with this antibody, as well as in the development of other therapeutic antibodies with maximum target specificity under various conditions.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
